Renaissance Technologies’s Enveric Biosciences ENVB Stock Holding History

Renaissance Technologies’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.2K	Buy	+32,058	New	+$77K	﹤0.01%	3056
2025 Q3	–	Sell	-3,084	Closed	-$44.8K	–	3601
2025 Q2	$44.8K	Buy	+3,084	New	+$46.7K	﹤0.01%	3409
2023 Q3	–	Sell	-95	Closed	-$58K	–	3769
2023 Q2	$58K	Buy	+95	New	+$46.2K	﹤0.01%	3586
2022 Q3	–	Sell	-121	Closed	-$234K	–	4102
2022 Q2	$234K	Sell	121 -100	-45%	-$213K	﹤0.01%	3578
2022 Q1	$657K	Buy	221 +159	+256%	+$702K	﹤0.01%	3008
2021 Q4	$515K	Buy	62 +7	+13%	+$98.4K	﹤0.01%	3060
2021 Q3	$1.02M	Buy	+55	New	+$1.07M	﹤0.01%	2534
2019 Q3	–	Hold	0	–	-$56K	–	3487
2019 Q2	–	Hold	0	–	–	–	3444
2019 Q1	–	Hold	0	–	-$12K	–	3502
2018 Q4	–	Hold	0	–	–	–	3332

Other funds holding ENVB

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies's ENVB Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Enveric Biosciences (ENVB) in Q2 2026: 32,058 shares worth $44.2K. The stake represents ﹤0.01% of the portfolio and ranks #3056 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in ENVB as recently as Q2 2025.

Renaissance Technologies first reported a position in ENVB in Q3 2021 and has held it in 7 quarters since. The position peaked at $1.02M in Q3 2021. 25 funds tracked by Wall St. Rank hold ENVB as of Q2 2026.

Renaissance Technologies held 32,058 shares of Enveric Biosciences worth $44.2K as of Q2 2026.
Enveric Biosciences was a new Renaissance Technologies position in Q2 2026.
Enveric Biosciences made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3056 holding.
Renaissance Technologies first reported a position in Enveric Biosciences in Q3 2021 and has held it in 7 quarters since.
Renaissance Technologies's Enveric Biosciences position peaked at $1.02M in Q3 2021.
25 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.